US/UK/Canada

Share

Contacts

  • Elos Medtech AB (publ)
    Torsgatan 5B, 411 04 Göteborg
    +46 10 - 171 20 00
    http://www.elosmedtech.com

    • Quotes

    “We will continue to collaborate with our present customers, but also increase our collaboration with technical partners”
    Soren Olesen, Dental Business Director, Elos Medtech
    “Keeping a close dialogue with our partners and maintaining a high level of competence has led to a product portfolio with the right focus – simple and innovative dental products for an open digital workflow.”
    Soren Olesen, Dental Business Director, Elos Medtech
    Elos Medtech is excited to highlight orthopaedics as one of the primary areas of focus and to execute on our market specific strategies. This is a natural step toward achieving our growth targets and capitalizing on our 2015 acquisition of Onyx Medical
    Jan Wahlström, CEO and President.
    Pick a time period -
    Tags ( Active)

    Elos Medtech Interim Report 1 January – 30 September, 2023

    July – September 2023 · Net sales for the third quarter amounted to SEK 251.2 (231.5) million, an increase of 8.5 percent compared to the same quarter last year. Net sales in local currencies increased by 4.3 percent. · Operating profit amounted to SEK 31.7 (37.7) million, corresponding to an operating margin of 12.6 (16.3) percent. · Profit after net financial items amounted to SEK 30.9 (29.0) million. Net financial items were positively affected by exchange rate differences of SEK 7.5 (-5.3) million and totaled SEK -0.8 (-8.7) million. · Cash flow from operating activities

    Elos Medtech Interim Report January 1 – June 30, 2023

    April – June 2023 · Net sales for the second quarter amounted to SEK 269.8 (233.1) million, an increase of 15.8 percent compared to the same quarter last year. Net sales in local currencies increased by 9.5 percent. · Operating profit amounted to SEK 30.1 (37.8) million, corresponding to an operating margin of 11.2 (16.2) percent. · Profit after net financial items amounted to SEK 13.7 (38.8) million. Net financial items were negatively affected by exchange rate differences of SEK -8.6 (3.6) million and totaled SEK -16.4 (1.1) million. · Cash flow from operating activities was

    Elos Medtech Interim Report January 1 - March 31, 2023

    January – March 2023 · Net sales for the first quarter amounted to SEK 267.2 (194.5) million, an increase of 37.4 percent compared to the same quarter last year. Net sales in local currencies increased by 29.5 percent. · Operating profit amounted to SEK 44.4 (29.2) million, corresponding to an operating margin of 16.6 (15.0) percent. · Profit after net financial items amounted to SEK 30.8 (29.8) million. Net financial items were negatively affected by exchange rate differences of SEK -4.7 (0.8) million and totaled SEK -13.6 (0.6) million. · Cash flow from operating activities

    Elos Medtech Interim Report January 1 - September 30, 2022

    July – September 2022 · Net sales for the third quarter amounted to SEK 231.5 (187.2) million, an increase of 23.7 percent compared to the same quarter last year. Net sales in local currencies increased by 12.4 percent. · Operating profit amounted to SEK 37.7 (24.2) million, corresponding to an operating margin of 16.3 (12.9) percent. Operating profit in the previous year includes a charge of SEK 11.8 million related to transaction costs in connection with the completion of the offer from the new majority owner. · Profit after net financial items amounted to SEK 29.0 (23.3)

    Elos Medtech Interim Report January 1 - June 30, 2022

    April – June 2022 · Net sales for the second quarter amounted to SEK 233.1 (181.0) million, an increase of 28.8 percent compared to the same quarter last year. Net sales in local currencies increased by 19.7 percent. · Operating profit amounted to SEK 37.8 (26.5) million, corresponding to an operating margin of 16.2 (14.7) percent. · Profit after net financial items amounted to SEK 38.8 (22.8) million. Net financial items were positively affected by exchange rate differences of SEK 3.6 (-0.9) million and totaled SEK 1.1 (-3.7) million. · Profit after tax amounted to SEK 29.7 (

    Elos Medtech Interim Report January 1 - March 31, 2022

    January – March 2022 · Net sales for the first quarter amounted to SEK 194.5 (171.2) million, an increase of 13.6 percent compared to the same quarter last year. Net sales in local currencies increased by 7.6 percent. · Operating profit amounted to SEK 29.2 (25.0) million, corresponding to an operating margin of 15.0 (14.6) percent. · Profit after net financial items amounted to SEK 29.8 (27.1) million. Net financial items were positively affected by exchange rate differences of SEK 0.8 (2.8) million and totaled SEK 0.6 (2.1) million. · Profit after tax amounted to SEK 23.0 (

    Elos Medtech Interim Report January 1 - September 30, 2021

    GOOD DEVELOPMENT IN ALL BUSINESS AREAS July - September 2021 · Net sales for the third quarter amounted to SEK 187.2 (147.9) million, an increase of 26.6 percent compared to the same period last year. Net sales in local currencies increased by 27.1 percent. · Operating profit for the year was SEK 24.2 (17.9) million, corresponding to an operating margin of 12.9 (12.1) percent. In the third quarter of last year government grant and subsidies due to Covid-19 had a positive impact of SEK 4.4 million on operating profit. · Operating profit includes a charge of SEK 11.8 million

    Elos Medtech Interim Report January 1 - June 30, 2021

    A STRONG QUARTER WITH CONTINUED GROWTH April - June 2021 · Net sales for the second quarter amounted to SEK 181.0 (118.3) million, an increase of 53 percent compared with the same period last year. Net sales in local currencies increased by 63 percent. · Operating profit amounted to SEK 26.5 (14.9) million, corresponding to an operating margin of 14.7 (12.6) percent. In the second quarter of last year government grant and subsidies due to Covid-19 had a positive impact of SEK 38.9 million on operating profit. · Earnings after net financial items amounted to SEK 22.8 (9.1)

    Elos Medtech Interim Report January 1 - March 31, 2021

    A POSITIVE START TO THE YEAR January - March 2021 · Net sales for the first quarter amounted to SEK 171.2 (158.9) million, an increase of 7.7 percent compared to the same quarter last year. Net sales in local currencies increased by 14.2 percent. · Operating profit increased to SEK 25.0 (11.9) million, corresponding to an operating margin of 14.6 (7.5) percent. · Profit after net financial items increased to SEK 27.1 (6.6) million. Exchange rate differences and revaluation of interest rate swaps had a positive impact on net financial items of SEK 2.8 (2.2) million and SEK 2.1 (

    Elos Medtech Interim Report January - September 2020

    A QUARTER OF STRONG RECOVERY July - September 2020 • Net sales for the third quarter amounted to SEK 147.9 million (157.1), a decrease of 5.9 percent compared to the same period last year. Net sales in local currencies decreased by 1.7 percent.• Operating profit was SEK 17.9 (14.2) million, corresponding to an operating margin of 12.1 (9.0) percent.• Operating profit has been positively affected by SEK 4.4 million with respect to government support received owing to Covid-19.• The profit after financial items amounted to SEK 14.2 (11.4) million. In the quarter, net financial

    Elos Medtech Interim Report January 1 - June 30, 2020

    A RAPID CONVERSION AND EFFICIENCY MEASURES DELIVER RESULTS  April - June 2020• Net sales for the second quarter amounted to SEK 118.3 million (184.1), a decrease of 35.7 percent compared to the same period last year. After currency translation, the decrease was 36.2 percent.• Operating profit was SEK 14.9 (15.6) million, which represents an operating margin of 12.6 (8.5) percent.• Operating profit has been positively affected by SEK 37 million with respect to government support received owing to Covid-19.• The profit after financial items amounted to SEK 9.1 (8.6) million. Net

    Elos Medtech Interim Report January 1 - March 31, 2020

    A STABLE START TO THE YEAR IN AN UNCERTAIN ENVIRONMENT January–March 2020• Net sales for the first quarter totalled SEK 158.9 (189.9) million, a decrease of 16.3 percent on the same period the year before. After currency translation, the decrease was -18.4 percent.• In the first quarter of 2019, inventory of finished products worth SEK 13.3 million was sold to Brüel & Kjær. Excluding this sale, net sales for the period decreased by 10 percent.• The operating profit was SEK 11.9 (21.4) million, which represents an operating margin of 7.5 (11.3) percent.• Profit after net financial

    Elos Medtech Interim Report January 1 - September 30, 2019

    INCREASED PROFITABILITY THROUGH EFFICIENCIES July - September 2019 • Net sales for the third quarter increased to SEK 157.1 (154.1) million, which corresponds to organic growth of 1.9 percent. Taking into account currency conversions, growth was negative, -1.3 percent.• The operating profit was SEK 14.2 (11.8) million. Our operating margin for the third quarter of 2019 was 9.0 percent, up from 7.7 percent in the same period in 2018.• The profit after financial items was SEK 11.4 (7.7) million. Net financial items, which were not affected by exchange rate differences during the

    Elos Medtech Interim Report January 1 - June 30, 2019

    ROBUST GROWTH AND AN IMPROVED OPERATING MARGIN April - June 2019 • Net sales for the second quarter increased to SEK 184.1 (166.0) million, which corresponds to organic growth of 10.9 percent. After currency conversions, our growth rate was 7.1 percent.• Operating profit amounted to SEK 15.6 (5.2) million. Operating margin for the second quarter of 2019 was 8.5 percent, up from 3.1 percent in the same period in 2018.• Profit after net financial items was SEK 8.6 (5.2) million. Net financial items were negatively affected by a net exchange rate loss of SEK -3.9 (2.4) million and

    Elos Medtech Interim Report January 1 - March 31, 2019

    Continued healthy growth and improved operating margin • Net sales for the quarter increased and amounted to SEK 189.9 (155.7) million, which corresponds to organic growth of 22.0%. After currency adjustments, our growth rate was 15.2%. During the quarter, a finished goods warehouse of SEK 13.3 million was sold to Bruel & Kjaer.• Excluding sales of finished goods, organic growth was 13.4% and adjusted for currency effects 6.8%.• Operating profit amounted to SEK 21.4 (10.9) million. Operating margin in the first quarter of 2019 was 11.3%, compared to 7.0% in the first quarter of 2018.

    Elos Medtech - Interim report January 1 - March 31, 2018

    Continued growth·Net sales for the quarter increased and amounted to SEK 155.7 million (140.9), corresponding to organic growth of 10.5%. After currency adjustments, growth was 11.3%. ·Operating profit amounted to SEK 10.9 million (13.3). The operating margin in the first quarter of 2018 was 7.0%. ·Profit after financial items amounted to SEK 9.6 million (9.6). Net financial items were positively affected by foreign exchange effects in the amount of SEK 0.8 million (-1.4). ·Profit after tax amounted to SEK 7.1 million (7.2), which corresponds to SEK 1.15 (1.19) per

    Elos Medtech - Interim report 1 January - 30 September, 2017

    Growt in several market segments in Q3• Net sales for the first nine months of the financial year increased and amounted to SEK 429.0 M (418.7), corresponding to growth of 2.5%.• Operating profit totalled SEK 36.1 M (39.7).• Profit after net financial items was SEK 20.7 M (32.1). Net financial items were negatively affected by exchange rate differences of SEK -8.4 M (1.1).• Profit after tax was SEK 15.1 M (23.5), corresponding to SEK 2.50 (3.88) per share.• Cash flow from operations was SEK 42.9 M (73.3), and after investments SEK 25.2 M (53.7). CEO, Jan Wahlström, comments

    Elos Medtech AB – earlier release of Q3 2017 report

    Elos Medtech AB announces that the release of the interim report for the 3rd quarter 2017 is moved from October 27th to October 24th. Elos Medtech is one of the leading development and production partners for medical technology products and components in the world, such as dental and orthopedic implants and instruments. The operations are conducted at facilities in Sweden, Denmark, China and the US. Customers are internationally active medical technology companies. Elos Medtech Group’s turnover is approximately MSEK 560 and has about 520 employees. The Group has been traded on NASDAQ

    Elos Medtech Interim Report January 1 - June 30, 2017

    High sales growth within Dental Implant Systems and increased market investments·Net sales for the first half of the year increased and amounted to SEK 296.5 M (292.0), corresponding to organic growth of 1.5%. ·Operating profit totalled SEK 26.8 M (28.0). ·Profit after net financial items amounted to SEK 15.5 M (21.3). Net financial items were negatively impacted by exchange rate differences of SEK - 6.7 M (-0.2). ·Profit after tax amounted to SEK 12.1 M (15.1), corresponding to SEK 2.00 (2.49) per share. ·Cash flow from operations was SEK 32.5 M (44.6) and

    Elos Medtech Interim report, 1 January - 31 March , 2017

    The global market for medical technology products is growing in a number ofour business areas and we see favourable growth opportunities.•   Net sales amounted to SEK 140.9 M (140.4), corresponding to organic growth of 0.4%. · Operating profit totalled SEK 13.3 M (12.0).  · Profit after net financial items amounted to SEK 9.6 M (6.8). Net financial items were negatively impacted by exchange-rate differences of SEK 1.4 M (neg: 1.7). · Profit after tax amounted to SEK 7.2 M (4.9), corresponding to SEK 1.19 (0.80) per share. · Cash flow was SEK 11.9 M (20.5) from

    Elos Medtech - Interim report, 1 January – 30 September 2016

    Continued improved earnings and strong cash flow• Net sales increased to SEK 418.7 M (367.7) which, adjusted for exchange-rate fluctuations, corresponds to a rise of 14.7%, of which organic growth was 2.1%. • Operating profit improved to SEK 39.7 M (25.5, adjusted for non-recurring items of 34.0). • Profit after net financial items totalled SEK 32.1 M (20.0). Net financial items were positively affected by exchange-rate differences of SEK 1.1 M (0.1).  • Profit after tax amounted to SEK 23.5 M (12.9), corresponding to SEK 3.88 (2.13) per share. • Cash flow from operating

    Elos Medtech Interim report, 1 January – 30 June 2016

    Sales growth and improved operating profit• Net sales for the first half of the year increased to SEK 292.0 M (244.6), which adjusted for exchange-rate fluctuations corresponds to an increase of 20.2%, of which organic growth was 1.1%. • Operating profit totalled SEK 28.0 M (19.4, adjusted for non-recurring items of 26.4). • Profit after net financial items totalled SEK 21.3 M (16.7). Net financial items were negatively impacted by exchange-rate differences of SEK 0.2 M (pos: 0.3).  • Profit after tax amounted to SEK 15.1 M (11.3), corresponding to SEK 2.49 (1.87) per share. •

    Elos Medtech Interim report, 1 January-31 March 2016

    • Net sales amounted to SEK 140.4 M (105.5), which adjusted for exchange-rate fluctuations corresponds to an increase of 34.5%, of which organic growth was negative 2.0%. • Operating profit totalled SEK 12.0 M (10.2 before non-recurring items of 4.5). • Profit after net financial items totalled SEK 6.8 M (7.6). Net financial items were negatively impacted by exchange-rate differences of SEK negative1.7 M (2.9). • Profit after tax amounted to SEK 4.9 M (5.6), corresponding to SEK 0.80 (0.93) per share. • Cash flow from operating activities was SEK 20.5 M (12.1) and, after

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media

    Twitter